Who
William J. Chase
Director
Company insider
Files Form 4 as: Director, Grail; Director, Intellia Therapeutics; EVP, Finance & Administration, AbbVie.
In numbers
- Trades disclosed
- 94
- Buys
- 2
- Sells
- 7
- Bought
- $3.0M
- Sold
- $17.4M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 7 Feb 2013
- Last trade
- 15 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 16 Oct 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Code A | $21K153 at $135.46 | filing |
| 15 Jul 2026filed 16 Jul 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Code A | $21K276 at $74.36 | filing |
| 15 Jul 2026filed 16 Jul 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Code A | $21K276 at $74.36 | filing |
| 18 Jun 2026filed 22 Jun 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Code A | $350K5,491 at $63.74 | filing |
| 18 Jun 2026filed 22 Jun 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Code A | $350K5,491 at $63.74 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —9,200 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,300 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,300 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —9,200 at $0.00 | filing |
| 15 Apr 2026filed 17 Apr 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Code A | $20K408 at $49.79 | filing |
| 15 Apr 2026filed 17 Apr 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Code A | $20K408 at $49.79 | filing |
| 15 Jan 2026filed 16 Jan 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Code A | $21K213 at $97.44 | filing |
| 15 Jan 2026filed 16 Jan 2026 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Code A | $21K213 at $97.44 | filing |
| 15 Oct 2025filed 16 Oct 2025 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Code A | $21K275 at $75.52 | filing |
| 20 Aug 2025filed 22 Aug 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Bought | $1.0M100,000 at $10.03 | filing |
| 15 Jul 2025filed 17 Jul 2025 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Code A | $21K533 at $38.53 | filing |
| 11 Jun 2025filed 13 Jun 2025 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —11,450 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 29 May 2025filed 30 May 2025 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Code A | $250K6,082 at $41.10 | filing |
| 15 Apr 2025filed 16 Apr 2025 | GRAL GrailDiagnostics & Labs | SEC FORM 4 Code A | $20K784 at $25.94 | filing |
News
AbbVie (NYSE:ABBV) & TScan Therapeutics (NASDAQ:TCRX) Financial ComparisonABBV · tickerreport.com · 22 Oct 2026AbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE® in Platinum-Resistant Ovarian CancerABBV · cantechletter.com · 21 Oct 2026AbbVie vs. Bristol Myers: Is AbbVie's Valuation Premium Worth Paying?ABBV · insidermonkey.com · 19 Oct 2026Contrasting Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI)NTLA · tickerreport.com · 19 Oct 2026Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)NTLA · themarketsdaily.com · 19 Oct 2026Intellia Therapeutics Names New CMO To Oversee Clinical And Regulatory FunctionsNTLA · rttnews.com · 13 Oct 2026
0 headlines in the last 90 days name William J. Chase; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.